Literature DB >> 29799383

Lessons from the on-site quality audit of data transmitted to the French cystic fibrosis registry.

Nadine Pellen1, Laëtitia Guéganton2, Dominique Pougheon Bertrand3, Gilles Rault4.   

Abstract

BACKGROUND: The French Cystic Fibrosis Registry takes a census of the population of patients and records their annual data transmitted by Cystic Fibrosis Centers (CFCs). Quality of patient data has been a focus in the past years, with the implementation of automated controls before data integration. The objective was to assess, at the 14 CFCs trained in the quality improvement named Hospital Program to Improve Outcomes and Expertise in Cystic Fibrosis (PHARE-M), the quality of the 2012 and 2013 data transmitted to the French Registry with respect to the rules established to obtain forced expiratory volume in 1 second (FEV1%) and anthropometric data.
METHODS: The clinical researcher selected 20 patients at each CFC from age ranges corresponding to different visit frequencies and measurement procedures in order to reach saturation of error causes. The control consisted in comparing source data, pulmonary function tests (PFTs), patient records, and data in the Registry.
RESULTS: The audit focused on 242 patients, 2455 consultations and 1855 PFTs. Less than 5% of data concerning weight, height, or FEV1 (L) in the patient records files had discrepancies with source data. Discrepancies on patient height between patient records and PFT files were found in 11% of cases. For one hundred and ten patients (45%), anomalies were found between the patient record and the Registry for the FEV1% and the associated anthropometric measurements mainly related to the interpretation of the selection rule of the venue corresponding to the "best spirometry in the year" and the reference standard used (local standards versus Knudson reference equations). For the 33 children in the age range of 6-17 years old (27% out of 120 children records controlled), the FEV1% value in the Registry presented an average deviation of +4.25% (min. = -9.3%; max. = +16.9%; median = 4%) with the value from the Patient record.
CONCLUSIONS: This first on-site quality audit of the data transmitted to the Registry pointed out variability in the measurement process at the CFCs. The rule for selecting the data for the Registry was applied differently at some CFCs, and various local References for the FEV1% calculation were used. Avenues for improvement have been identified.

Entities:  

Keywords:  Cystic fibrosis; Measurement recommendations; Quality audit; Registry

Mesh:

Year:  2018        PMID: 29799383      PMCID: PMC6225547          DOI: 10.1186/s13023-017-0750-x

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  5 in total

1.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

Review 2.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.

Authors:  P H Quanjer; G J Tammeling; J E Cotes; O F Pedersen; R Peslin; J C Yernault
Journal:  Eur Respir J Suppl       Date:  1993-03

3.  Future trends in cystic fibrosis demography in 34 European countries.

Authors:  Pierre-Régis Burgel; Gil Bellis; Hanne V Olesen; Laura Viviani; Anna Zolin; Francesco Blasi; J Stuart Elborn
Journal:  Eur Respir J       Date:  2015-03-18       Impact factor: 16.671

4.  Using the new UK-WHO growth charts.

Authors:  Charlotte M Wright; Anthony F Williams; David Elliman; Helen Bedford; Eileen Birks; Gary Butler; Magda Sachs; Robert J Moy; Timothy J Cole
Journal:  BMJ       Date:  2010-03-15

5.  Quality of care in cystic fibrosis: assessment protocol of the French QIP PHARE-M.

Authors:  Dominique Pougheon Bertrand; Emmanuel Nowak; Clémence Dehillotte; Lydie Lemmonier; Gilles Rault
Journal:  Orphanet J Rare Dis       Date:  2018-02-08       Impact factor: 4.123

  5 in total
  3 in total

1.  Introduction of a collaborative quality improvement program in the French cystic fibrosis network: the PHARE-M initiative.

Authors:  Dominique Pougheon Bertrand; Guy Minguet; Pierre Lombrail; Gilles Rault
Journal:  Orphanet J Rare Dis       Date:  2018-02-08       Impact factor: 4.123

2.  Quality of care in cystic fibrosis: assessment protocol of the French QIP PHARE-M.

Authors:  Dominique Pougheon Bertrand; Emmanuel Nowak; Clémence Dehillotte; Lydie Lemmonier; Gilles Rault
Journal:  Orphanet J Rare Dis       Date:  2018-02-08       Impact factor: 4.123

3.  Strategies for care quality improvement in Cystic Fibrosis.

Authors:  Gilles Rault; Pierre Lombrail
Journal:  Orphanet J Rare Dis       Date:  2018-02-08       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.